In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Absence of cardiac siderosis at cardiac magnetic resonance in patients with dysmetabolic hyperferritinemia.

Session Poster session 1

Speaker Patrizia Pedrotti

Congress : EuroCMR 2019

  • Topic : imaging
  • Sub-topic : Cardiac Magnetic Resonance: Myocardium
  • Session type : Poster Session
  • FP Number : P179

Authors : ABE Longo (Milano,IT), L Valenti (Milano,IT), S Pelusi (Milano,IT), A Milazzo (Milan,IT), G Quattrocchi (Milan,IT), P Sormani (Milan,IT), AL Facanzani (Milano,IT), S Fargion (Milano,IT), C Giannattasio (Milan,IT), A Vanzulli (Milan,IT), P Pedrotti (Milan,IT)

ABE Longo1 , L Valenti1 , S Pelusi1 , A Milazzo2 , G Quattrocchi2 , P Sormani2 , AL Facanzani1 , S Fargion1 , C Giannattasio2 , A Vanzulli3 , P Pedrotti2 , 1University of Milan - Milano - Italy , 2Niguarda Ca' Granda Hospital, Angelo De Gasperis, Department of Cardiovascular - Milan - Italy , 3Niguarda Ca' Granda Hospital, Radiology - Milan - Italy ,

European Heart Journal - Cardiovascular Imaging ( 2019 ) 20 ( Supplement 2 ), ii138


The clinical condition of dysmetabolic hyperferritinemia (DHF) is defined in the presence of non-alcoholic fatty liver disease (NAFLD), metabolic syndrome alterations, and increased ferritin levels. Hyperferritinemia and iron stores have been associated with liver damage and susceptibility to vascular damage in NAFLD. However, conflicting data have been reported on the role of iron in atherosclerosis and heart disease, with recent evidence suggesting that excess iron induces vascular damage and could predispose to heart disease. We aimed at assessing cardiac function and the presence of cardiac siderosis in DHF with cardiac magnetic resonance (CMR).


Between 2009 and 2018 we enrolled patients (pts) with DHF (pts with NAFLD with alcohol assumption <  20 and 30 g/day for females and males, at least one feature of the metabolic syndrome, ferritin > 450 µg/L, normal or only mildly increased transferrin saturation); pts with iron storage disease and inflammatory disease were excluded. Pts underwent CMR on a 1.5 Tesla clinical scanner, the protocol included SSFP cines, dark-blood multi-echo T2* sequence and MOLLI T1 mapping sequence. Images were analyzed with validated commercial software.


Thirty-four pts were enrolled, mean age was 58±13 years, 29 were men (85%), mean ferritin was 903±332 µg/L. Left ventricular end diastolic and end systolic indexed volumes (EDV-I 68±17 ml/m2; ESV-I 23±7ml/m2), indexed mass (68±16 g/m2) and ejection fraction (66±8%) were normal. Mean T2* was within normal range (33±6 ms), mean MOLLI T1 was (976±27ms). As previously demonstrated, there was no correlation between T2* values and ferritin, neither between T2* and MOLLI T1 values, being T2* in the normal range. There was a significant but weak inverse relation between ferritin and MOLLI T1-values (p< 0.05,  R= -0.34).


In a small cohort of pts with DHF, CMR demonstrated normal cardiac systolic function and absence of cardiac siderosis. Unlike T2* values, MOLLI T1 values were weakly related to ferritin values. Further studies are warranted to explore subtler cardiac dysfunction in DHT and to understand if MOLLI T1 could be correlated to hyperferritinemia and reflect mild cardiac siderosis in these pts.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are